



Individual Investigator Research Grant Award
Request for Proposal (RFP) for 2026 - 2028 Cycle
Grant Application
PROGRAM GUIDELINES
Deadline: May 16, 2026

The RYR-1 Foundation is pleased to invite investigators to submit a Request for Proposal (RFP) focused on the following specific Research Priority Areas (RPAs):

- **Readthrough Therapies for RYR-1-Related Disease (RYR-1-RD) due to Nonsense Variants**
 - *This RPA is a focus of this RFP for the following reasons: 1) The clinical severity of RYR-1-RD patients with nonsense variants, 2) The ongoing development of a nonsense RYR-1-RD [mouse model](#) (see details below), and 3) The growing field of readthrough therapies, including, but not limited to, small molecules and tRNA-based therapies.*

- **Variant-Agnostic Therapeutic Strategies for Dominant Forms of RYR-1-Related Myopathy**
 - *This RPA is a focus of this RFP for the following reasons: 1) The large number of individuals affected by dominant forms of RYR-1-related myopathy and 2) A variant-agnostic therapy has the potential to treat many of these individuals in a more expeditious fashion due to reduced technical, financial, and regulatory hurdles.*

Further details, including different budget limits, on these RPAs can be found on **pages 2-3 below**.

Eligibility:

Applicants must hold a Ph.D., M.D., D.V.M., D.O., or equivalent degree and have a faculty position/equivalent at a domestic/foreign nonprofit organization, or public/private institution (such as a university, college, medical school, hospital, research institute, or laboratory).

Submission & Review Timeline:

- **Application Deadline:** May 16, 2026
- **[Online Application via ProposalCentral](#)**
 - You may access your saved application by clicking the 'Home' tab in ProposalCentral.
- **Funding Decisions Announced By:** July 17, 2026

If you have any questions, please contact [Lena Leghart](#), Program Manager.

Summary of Required Application Information:

- Title Page (Project Title) of the RYR-1-Related Diseases (RYR-1-RD) Project
- Enable Other Users to Access this Proposal
- Information/Acknowledgements
- Applicant/PI
- Institution & Contacts
- Key Personnel (including a short *curriculum vitae* or NIH Biosketch)
- Abstract
 - Lay Abstract
 - Specific Aims and Rationale
- Impact Statement
- Preliminary/Supporting Data
- Budget Period Detail
- Budget Summary and Justification
- Organization Assurances
- Attachments
 - *Curriculum vitae* and/or NIH Biosketch
 - Gantt Chart
 - Preliminary/Supporting Data
 - Detailed Project Description
- Signature Page

DESCRIPTION:

Individual Investigator Research Grant Awards are designed to concentrate research in areas that will have the greatest potential to move forward effective treatments and cures for RYR-1-RD.

RESEARCH PRIORITY AREA (RPA)s:

Applications for these RPAs must be focused on the following research priority areas:

Readthrough Therapies for RYR-1-RD Due to Nonsense Variants

NOTE: The RYR-1 Foundation recently contracted ingenious targeting laboratory to generate a ***RYR1* nonsense [mouse model](#)** that is currently in development and projected to be available in the spring/summer 2026. If desired by the PI, this mouse line (along with a second heterozygous missense T4709M *RYR1* mouse line) will be made available to the awarded investigator.

Variant-Agnostic Therapeutic Strategies for Dominant Forms of RYR-1-Related Myopathy

NOTE: Although the focus of this RPA is the *myopathy* associated with dominant forms of RYR-1-RD, research proposals may incorporate cellular/animal models associated with RYR-1-related *malignant hyperthermia* and/or *exercise-induced rhabdomyolysis*.

For more information on currently available mouse models, please go to our [RYR-1-RD mouse model webpage](#).

To obtain these mice, please contact [Lena Leghart](#), Program Manager.

AWARD:

PLEASE NOTE THAT THESE RPAs HAVE DIFFERENT BUDGET LIMITS

Readthrough Therapies for RYR-1-RD due to Nonsense Variants: The total award will be up to **\$200,000 USD budgeted over a period of two years** (up to **\$100,000 USD per year**). Please note, total grant funding will not exceed \$200,000 USD.

Variant-Agnostic Therapeutic Strategies for Dominant Forms of RYR-1-Related Myopathy: The total award will be up to **\$120,000 USD budgeted over a period of two years** (up to **\$60,000 USD per year**). Please note, total grant funding will not exceed \$120,000 USD.

Renewal is based on both documented progress and on availability of funds. The award may be used to support the salaries of research trainees (graduate students, postdoctoral or clinical fellows); technical staff; research animals; research supplies, and instrument usage fees. Partial support for the Principal Investigator's salary is permitted, equivalent to the ratio of effort up to 10%, but not more than \$15,000 per year, plus a proportionate ratio of fringe benefits.

Note: The RYR-1 Foundation and its Directors do not provide funds for indirect, administrative, or overhead costs. In addition, The RYR-1 Foundation does not pay for costs related to construction or renovation.

Purchase of capital equipment is generally not supported by The RYR-1 Foundation. Capital equipment is defined as a permanent or semi-permanent apparatus, device, or system costing more than \$5,000 per device or system. Applicants must obtain prior approval from The RYR-1 Foundation Chair/Co-Chair(s) of Research to submit an application proposing to purchase capital equipment. If approval is to be granted, all such equipment requests must be well justified in the budget section of the application and in the description of the proposed project.

Letters of collaboration must be included, and collaborations with experts in RYR-1-RD are strongly encouraged.

If any of the investigators have either an active or pending grant on RYR-1-RD matters, a list should be provided in this application, including the funding agency, title of the grant, names of investigators, percentage efforts, duration of the grant, and budget.

INSTITUTIONAL CONSIDERATIONS:

Half of the first year's financial award will be delivered to the host institution upon activation of the project, and the remainder will be provided in follow-up tranches, dependent upon our receipt of an acceptable progress report at the end of the initial six months (or earlier if presented at a meeting of The RYR-1 Foundation Scientific Advisory Board and/or Research Workshops). Alternative payment mechanisms (e.g., reimbursement to the P.I., personally, rather than to the institution) may occasionally be acceptable under specified and well documented circumstances, but must be approved in writing, and in advance, by the Chair/Co-Chair(s) of Research of The RYR-1 Foundation.

The RYR-1 Foundation uses the "Just in Time" concept. Applicants may defer the following items until completion of peer review and just prior to funding: certification of the Institutional Review Board (IRB) and Institutional Biosafety Committee (BC); approval of the application's proposed use of human subjects and proposed use of recombinant DNA; verification of the Institutional Animal Care and Use Committee (ACUC) approval of the proposed use of live vertebrate animals; Health Insurance Portability and Accountability Act (HIPAA) compliance; and evidence of compliance with the requirement for education in the protection of human research participants.

Evidence of these approvals must be documented by submission of a signed Institutional Agreement Form (IAF) at the time of the award. If approvals are pending at the time of the award, The RYR-1 Foundation funding cannot be expended for research involving human subjects, recombinant DNA, and live vertebrate animals until the signed forms are submitted to document that the appropriate approvals have been obtained.

KEY PERSONNEL

Each Research Grant Application must be directed by a **single Principal Investigator** who is responsible for the overall conduct and management of the project. Co-Investigators are allowed, and must be identified and justified.

1. Identify all scientific and technical personnel involved in the proposed project. Identify all proposed collaborators in this section of the application and include letters of collaboration.
2. For all key personnel, include current and pending sources of ALL research support. For each source (federal, private, or commercial) provide: title, grant number, percent effort, funding amount, and budget period. This information should include total support for all current and proposed projects **AND** provide abbreviated CVs for all key personnel (NIH biosketch is preferred), listing only up to five **RELEVANT** publications. **DO NOT** include free-standing Abstracts; NIH Biosketch is preferred.

ABSTRACT

LAY ABSTRACT (1,500 characters)

Provide an abstract of the proposed research project, written **in lay terms** for a non-scientific audience. The abstract should contain non-confidential material that can be posted on The RYR-1 Foundation's website if the application is funded.

SPECIFIC AIMS AND RATIONALE (3,000 characters)

1. Describe the overall goal(s) and rationale for the proposed project. Numerically list the specific aims and correlate with Gantt Chart (uploaded in Attachments section). Describe the anticipated results to be achieved in each three-month period of the project. Note that successful applicants will be required to submit regular Progress Reports that detail accomplishments for each of the specific aims identified in the application.
2. If applicable, for clinical research projects, identify the specific disease(s) and patient population(s) to be studied. Include genomic diagnosis whenever possible.

IMPACT (3,000 characters)

State why this research is important and how it will make a significant difference in achieving The RYR-1 Foundation's mission of finding effective treatments or a cure for RYR-1-RD.

PRELIMINARY/SUPPORTING DATA (3,000 characters)

Describe existing experimental data or prior clinical research that support(s) the soundness and feasibility of the proposed experiments. Include evidence of in vitro and/or in vivo experiments, if applicable, that demonstrate the relevance of the proposed experiments for advancing therapeutic or preventive interventions.

BUDGET SUMMARY AND JUSTIFICATION

Budget Justification (3,000 characters)

ATTACHMENTS (Uploaded in this section)

APPLICANT BIOSKETCH

NIH Biosketch (preferred) or equivalent.

DETAILED PROJECT DESCRIPTION (5 page limit)

Experimental Plan and Methods: For each specific aim, describe the experimental design, procedures, and methods to be used. ***The level and amount of detail utilized in an NIH investigator-initiated research project grant application is not required by The RYR-1 Foundation.*** However, applicants must include sufficient information so that reviewers can understand the proposed experiment, its soundness, feasibility, and importance for advancing the knowledge of RYR-1-RD.

Applications proposing **research using human samples** must provide the information delineated below.

NOTE: If IRB approval is not required in order to conduct the proposed clinical study using human samples, then such projects are considered non-clinical, and applicants are not required to provide the information/materials listed below.

GANTT CHART

Key milestones and timelines for the proposed research must be included in this section. A chronological Gantt Chart to illustrate these events must be included.

PRELIMINARY/SUPPORTING DATA (1 page limit)

SIGNATURE PAGE

Applicant
Signing Official
Financial Officer

Clinical Research Requirements (if applicable):

A. Study Description: A description of the proposed clinical study, including (a) hypothesis and study objectives; (b) study population(s) and relevance of the proposed study to clinical disease/patient outcome; (c) study design, methodologies, and the scientific rationale, including supporting data from completed basic, preclinical and clinical research, and the feasibility and appropriateness of applying such supporting data to the design and execution of the proposed clinical study; (d) statistical analysis plan and, where applicable, including sample sizes power calculations; and (f) plan for receipt, storage and distribution of human, animal, or stem cell samples.

B. Human Samples: Documentation of the ability to acquire human samples prospectively or retrospectively, including obtaining samples from planned, ongoing or completed clinical studies/trials sponsored by any source. This should include written agreements between the applicant institution, the Investigational New Drug (IND), and clinical trial sponsor.

C. Informed Consent: Please submit a copy of the approved or proposed informed consent form(s) to be used for collection of patient samples (**include in Appendix Materials; this information does not count against the 5-page proposal limit**).

D. Milestones and Timelines: Delineate key milestones and timelines for the proposed research project. Milestones are intended to define the specific stages and/or steps involved in accomplishing the stated aims, and are to incorporate timelines for the initiation, execution, and completion of each specific stage or step. The number/types of milestones will vary depending on the goals and outcomes of the proposed project. This information should be shown in a Gantt Chart.

E. Collaborative Plans: *The RYR-1 Foundation strives to foster the sharing of information.* Therefore, include specific plans for collaboration with other investigators to share research materials, methodologies/technologies, animal models, patient assessment tools and results, and both positive and negative findings.

F. Future Relevance: If the aims of the application are achieved, **describe how scientific knowledge or clinical practice will be advanced.** Include a brief discussion on the anticipated effects of the study on the concepts, methods, technologies, treatments, or services that drive the field of research on RYR-1-RD.

G. References: Provide a list of bibliographic references for: (a) up to **ten** publications, but only if relevant to support the science for the proposed research; and (b) up to **three** personal pertinent reprints representing the applicant's research (PDF format for each reprint). This information does **not** count against the page limits.